SEC Form 4 · accession 0001192482-18-000047
Recro Pharma, Inc. · REPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Celano
Officer — Chief Operating Officer
Period of report
Jan 18, 2018
Accepted (ET)
Jan 22, 2018 · 5:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001588972
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 18, 2018 | M | 6,400 | — | A | 30,495 | D | |
| Common Stock | Jan 18, 2018 | F | 2,020 | $8.89 | D | 28,475 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jan 18, 2018 | M | 6,400 | D | — | — | Common Stock | 6,400 | 19,200 | D |
Explanation of responses
- F1Restricted stock units convert into common stock on a one-for-one basis.
- F2On January 18, 2017, the reporting person was granted 25,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.